In vivo discovery of immunotherapy targets in the tumour microenvironment. - Wikidata - awgldk - TriplyDB

In vivo discovery of immunotherapy targets in the tumour microenvironment.

In vivo discovery of immunotherapy targets in the tumour microenvironment.

http://www.wikidata.org/entity/Q33736396

about

The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance Big Data Offers Novel Insights for Oncolytic Virus Immunotherapy Resources for the design of CRISPR gene editing experiments Advances in immunotherapy for treatment of lung cancer Targeting Transcriptional Regulators of CD8+ T Cell Dysfunction to Boost Anti-Tumor Immunity Large molecular systems landscape uncovers T cell trapping in human skin cancer.Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing T-cell receptor gene therapy--ready to go viral?Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study Designing chimeric antigen receptors to effectively and safely target tumors T cell exclusion, immune privilege, and the tumor microenvironment Co-recruitment analysis of the CBL and CBLB signalosomes in primary T cells identifies CD5 as a key regulator of TCR-induced ubiquitylation Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic.Microenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.In vivo RNA interference screens identify regulators of antiviral CD4(+) and CD8(+) T cell differentiation.Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.Inducible RNAi in vivo reveals that the transcription factor BATF is required to initiate but not maintain CD8+ T-cell effector differentiation.Discovering cancer immunotherapy targets in vivo.Current advances in T-cell-based cancer immunotherapy High-throughput functional genomics using CRISPR-Cas9.Ex vivo engineered immune organoids for controlled germinal center reactions.Serine Phosphorylation of SLP76 Is Dispensable for T Cell Development but Modulates Helper T Cell Function.In vivo RNAi screens: concepts and applications.Phosphatase PP2A is requisite for the function of regulatory T cells.Ionic immune suppression within the tumour microenvironment limits T cell effector function.Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation.Molecular insights into the development of T cell-based immunotherapy for prostate cancer.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.Adoptive cellular therapy: a race to the finish line.Modulation of Immune Cell Functions by the E3 Ligase Cbl-b.Glioblastoma antigen discovery--foundations for immunotherapy.Synthetic biology in cell-based cancer immunotherapy.Tumor Microenvironment as a New Target for Tumor Immunotherapy of Polysaccharides.An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection.Role of "oncogenic nexus" of CIP2A in breast oncogenesis: how does it work?Genetic screens to study the immune system in cancer.Targeting PD-1/PD-L1 in lung cancer: current perspectives.HIV Receives a "One Two Knockout Punch".Mouse models in oncoimmunology.Advances in immunotherapy for the treatment of glioblastoma.

P2860

Q26739246-C54C0ED7-5017-4A52-A8E2-D5523A55C921 Q26767209-6287BC95-8205-439A-BEEF-8B10FA5756A9 Q26776435-2329D103-098E-4BE1-B1A2-493F61A09FC6 Q26778790-2654C2A1-DD9C-45A7-A662-676DEE2A5603 Q26782201-DE1A97F8-42AF-4DB8-AEE1-E6439B69F965 Q27302197-51B9593F-B12A-4256-93F8-277FA612CE16 Q27334215-877DDDC1-2E7F-441F-91BA-2A4B6E541142 Q28081611-82A20BBB-8229-4165-9E98-92C783027554 Q28084489-A245F5B6-1B53-499F-B7F5-E16B9A3F27DA Q28088526-4D4BC2A5-37D7-44F5-A028-FB3E67C5E0C3 Q28259872-10CD1740-9223-4336-BB14-8C983160B973 Q28771482-C1171B06-F1E9-4A7F-B20D-0EADD9679741 Q30364184-3A4E589C-682D-4DE7-821A-FB9A0A1FB3A0 Q33786788-6DEA5CD3-62CA-45BF-A3D8-CA6F5B90680D Q34160642-70DBDB0C-A869-49C1-AC06-6656920911B0 Q34608239-0209AA57-7CBA-46CF-BA6B-218F98E924C6 Q34985524-6047AF8A-B513-4751-9BE9-121C6F2D1D56 Q35210865-B7DD16FA-48EB-47D3-869E-DD17317EC385 Q35215158-F0251976-EED7-4D78-AB05-5EAE65001B39 Q35597703-48EE9F70-8B5A-4FFF-A573-DC94B47C5161 Q35812007-F098AB80-EBFE-428C-B0ED-402555C1299F Q36255620-D02C719C-D40C-41FA-9A9D-98DDB7C02F05 Q36736715-F68AB0FA-A9C8-43E9-90E7-89D0084704D1 Q36813735-9BF12862-4903-489D-B27F-A1EDEE98FD69 Q37548587-1AA14E55-CD14-4FEB-A23F-86EA8D3AD33A Q37554202-C90A9C44-C6F1-423B-9184-D8318A71AFD3 Q38254639-502E0B33-8AC3-48CE-9E5A-C76FB0005422 Q38264014-9FFDCA8B-6F95-4E75-BC16-C7AC1F560F94 Q38391528-A2A23EA3-A523-40CB-9573-4134F8D21B96 Q38393275-3D98C5A9-F690-4808-905F-824A1B0477C0 Q38516823-5FF3E09C-26A6-4CDC-AFC6-8054C72C956E Q38531361-4BE5D9EE-E928-427E-BAAA-136880106028 Q38606460-8D73700E-E5DE-4C11-A109-503DDDEB4B6D Q38647794-E1D9787E-B2CA-4B20-B2B8-9D5896DE0AC4 Q38648429-745F06AB-CF2F-4A4B-8A16-B60A944CC03B Q38866884-5A2D239A-3651-4997-A438-A9021210AE7F Q38956294-A3ECB203-A6F4-402D-A313-F5AAC476BA44 Q38957108-CA34ADE5-EA3C-4B53-B609-08864C48CC3C Q38968582-7AA768ED-7F9F-4D93-95E6-242699A6C85D Q38981383-162DC3B8-F41F-4230-8228-AD1FB2E28142

P2860

In vivo discovery of immunotherapy targets in the tumour microenvironment.

http://www.wikidata.org/entity/Q33736396

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@ast

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@en

type

label

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@ast

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@en

prefLabel

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@ast

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@en

P1433

Q33736396-71844951-43FE-4DC0-95B5-F39A11AB712F

P1476

Q33736396-423D794D-D592-4E94-AE02-C2877D7B8379

P2093

Q33736396-0A5B3424-F060-4CCB-A46D-BE64F2122E95

Q33736396-0FB7CA4D-25D7-4236-B62C-508D689BE88D

Q33736396-11B209B5-EF11-452C-8E1B-6B1661E6F20B

Q33736396-41D0BC39-4777-40AD-9846-D0428BFDCC2A

Q33736396-4ABD4D16-683A-420A-9D2C-C22C1E184CE2

Q33736396-4D761B09-8BF0-4CC5-ADA8-A12846BE906C

Q33736396-562401D7-BB85-4231-840B-2956F1845A84

Q33736396-62109B4B-CD73-4D76-9181-2BD496E26C07

Q33736396-62D546CC-0D19-4ECE-B173-BB9469434CCB

Q33736396-65316ACC-E0EE-455E-B203-8080CC94E7A0

P2860

Q33736396-03772BA5-ABB8-422B-93D2-7D648AC63864

Q33736396-09DE4DA5-AF75-4989-8D78-0C244964A14D

Q33736396-0C3C9ECA-FC62-46F6-9722-EFC8372374BB

Q33736396-131EFFFE-9CD0-46A1-914E-1278304D89D3

Q33736396-21D336BF-BB07-40A4-8395-28DBA6F6021B

Q33736396-3331DE1B-7905-445B-AB18-337A29342E34

Q33736396-33C81751-11BE-4E76-BD4C-9C01100768CB

Q33736396-3596E9FE-3958-4BC1-A6B9-4EEDA6791623

Q33736396-3B79A3BF-6A10-4783-8D53-06EE9DB70885

Q33736396-4D601296-9211-4549-A3C1-95C3DF89FA54

P2888

Q33736396-798C86D8-911D-47AC-A0AC-0744FF25639D

P304

Q33736396-C91C866E-87C0-4392-A1CF-A27E985D449D

P31

Q33736396-ED8C6E85-9253-4470-BF70-78FA9216DC4E

P356

Q33736396-F7D757E7-E0D2-4DEC-9444-3FC330508D11

P407

Q33736396-F188C325-8767-4BC6-8A71-8BC87DDB9DD7

P433

Q33736396-46E9572F-A179-4D7F-AA90-AC8DB545BCD2

P478

Q33736396-10ACE397-B470-4ECC-80DA-87C41D16FDDE

P50

Q33736396-9E2511BF-33EE-4C92-A389-AE3F3A8938EF

P577

Q33736396-5232E420-BDEA-412B-8AA9-2084605FC51C

P5875

Q33736396-D36C3D11-64F0-43CA-9015-E72EF0F4F210

P698

Q33736396-DC0C2645-26CD-44D8-9F3C-EE7C21979608

P921

Q33736396-3C966584-A2B7-4CF6-B475-27B54FFFB680

P932

Q33736396-9223DE37-45EF-4854-BF40-A3261C115776

P356

P1433

P1476

In vivo discovery of immunotherapy targets in the tumour microenvironment.

@en

P2093

Alexis J Torres

http://www.w3.org/2001/XMLSchema#string

David E Root

http://www.w3.org/2001/XMLSchema#string

Diana A Alvarez Arias

http://www.w3.org/2001/XMLSchema#string

Donald R Shaffer

http://www.w3.org/2001/XMLSchema#string

Glenn Dranoff

http://www.w3.org/2001/XMLSchema#string

Glenn S Cowley

http://www.w3.org/2001/XMLSchema#string

Harvey Cantor

http://www.w3.org/2001/XMLSchema#string

Hidde L Ploegh

http://www.w3.org/2001/XMLSchema#string

J Christopher Love

http://www.w3.org/2001/XMLSchema#string

Jennifer Brogdon

http://www.w3.org/2001/XMLSchema#string

P2860

Dephosphorylation of Carma1 by PP2A negatively regulates T-cell activation

Protein phosphatase 2A dephosphorylation of phosphoserine 112 plays the gatekeeper role for BAD-mediated apoptosis

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Tumor-specific Th17-polarized cells eradicate large established melanoma

Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Nivolumab plus ipilimumab in advanced melanoma.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

P2888

P304

52-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE12988

http://www.w3.org/2001/XMLSchema#string

P407

P433

7486

http://www.w3.org/2001/XMLSchema#string

P478

506

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259984859

http://www.w3.org/2001/XMLSchema#string

P698

24476824

http://www.w3.org/2001/XMLSchema#string

P921

P932

4052214

http://www.w3.org/2001/XMLSchema#string